HACARUS Begins Joint Anti-Cancer Drug Discovery Research with the Keio University School of Medicine

HACARUS Begins Joint Anti-Cancer Drug Discovery Research With The Keio University School Of Medicine

Exploring the homology between human cancers and mouse cancers by using mouse models that combine HACARUS’ AI capabilities with the medical expertise of Professor Hideyuki Saya from the Keio University School of Medicine’s Institute for Advanced Medical Research.


January 31th, 2022 – Kyoto, Japan – HACARUS INC, the leading provider of big insights from small data, announced a joint research project with the Keio University School of Medicine to elucidate the correlation between human and mouse cells and their response to anti-cancer drugs.

HACARUS CEO Kenshin Fujiwara expressed his excitement about this new venture, saying, “I am confident in our image analysis capabilities here at HACARUS. I think that by working together with Professor Saya, we will be able to gain a deeper understanding of the homology between humans and mice. If so, we can significantly contribute to the cancer treatment field by supporting the development of new anti-cancer drugs.”

Hideyuki Saya, a faculty member of the Institute for Advanced Medical Science at the Keio University School of Medicine, was also optimistic about this proposed research project, saying, “Characteristics of cancer tissues have previously been determined by the eyes of experienced pathologists. Diagnostic processes will be more efficient when AI-based systems enable extracting cancer features automatically from pathological images. Collaboration between HACARUS and our team consisting of pathologists, physicians, and basic scientists will demonstrate the competency of using mouse models to diagnose human cancers and developing new therapies.”

Even if the drugs developed are effective in treating the cancer cells transplanted into mice, it is unknown whether these drugs will be effective in humans. Saya’s Laboratory, led by Yoshimi Arima and Akiyoshi Kasuga, has established biliary tract cancer mouse models that recapitulate human cancers so as to improve the efficiency of drug discovery (*1). These models are used for the AI-based system to identify the features of human cancers.

Moving forward, HACARUS will continue to pursue research with the Keio University School of Medicine and other like-minded institutions that contribute to society through AI and sparse modeling.


HACARUS INC. provides big insights from small data. Since its founding in 2014, the company has supplied solutions in 100+ AI projects across Medical and Manufacturing fields. Headquartered in Kyoto, Japan, and backed by Osaka Gas and Miyako Capital (Kyoto University), among others, HACARUS technology continues to enable humans to make better, faster, and more reliable decisions based on data-driven insight. HACARUS’ proprietary AI engine was built using Sparse Modeling, a method that understands data like a human would – by its unique key features and is far more resource, time, and energy-efficient when compared to Deep Learning. To learn more, visit https://hacarus.com

About the Keio University School of Medicine

The Keio University School of Medicine was founded in 1917. The school’s vision is to unify basic science and clinical medicine. Since its founding, the school has educated physician scientists who continue to shape the future of medicine in Japan. To learn more about the Keio University School of Medicine, visit http://www.med.keio.ac.jp/en/


  1. Kasuga A, Semba T, Sato R, Nobusue H, Sugihara E, Takaishi H, Kanai T, Saya H, Arima Y: Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Cancer Sci. 2021

Subscribe to our newsletter

Click here to sign up